The use of ulipristal acetate (UPA) has been recently introduced in the treatment of uterine leiomyomas. This drug has proven useful to control menometrorrhagia and to reduce myoma size. In the case presented here, we show the benefits of UPA treatment in facilitating surgical removal of giant myomas in an infertile patient. In addition to myoma reduction and a better control of preoperative bleeding, the treatment with UPA reduced the duration and complexity of the surgery, as well as the area of uterine wall involved and the resulting scar. No side effects were observed and the patient became pregnant 6 months after the surgery and had a normal pregnancy and delivery. This case report shows the beneficial effects of UPA in the preoperative treatment of myomas which affect uterus function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995335 | PMC |
| http://dx.doi.org/10.1155/2016/5135780 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Promising selective progesterone receptor modulators: what's new in female contraception?
Expert Opin Investig Drugs
December 2024
Department of Obstetrics and Gynecology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Introduction: Selective progesterone receptor modulators (SPRMs), such as mifepristone and ulipristal acetate (UPA), have demonstrated high efficacy and safety as single-dose treatments for medication abortion and emergency contraception (EC). Other obstetrical and gynecologic applications have emerged, both for episodic and ongoing uses. The potential of these compounds to provide estrogen-free, ongoing contraception is promising; however, the rare, but serious, hepatic injury cases seen with UPA have put at least a temporary halt to further research in this area.
View Article and Find Full Text PDFWhite matter integrity upon progesterone antagonism in individuals with premenstrual dysphoric disorder: A randomized placebo-controlled diffusion tensor imaging study.
Prog Neuropsychopharmacol Biol Psychiatry
October 2024
Department of Women's and Children's Health, Science for Life Laboratory, Uppsala University, Sweden. Electronic address:
Article Synopsis
- PMDD is a severe form of premenstrual syndrome caused by hormonal changes, and the study investigates the effects of selective progesterone receptor modulation (SPRM) on brain white matter in affected patients.
- Researchers used diffusion tensor imaging to compare the effects of ulipristal acetate (an SPRM) and a placebo on white matter integrity before and after treatment in a controlled trial.
- Results showed that SPRM treatment did not significantly change white matter structure compared to placebo, although there were some differences in measurements that warrant further exploration.
Impact of Regulatory Interventions on Ulipristal Acetate 5 mg (Esmya) Use in Spain: An Interrupted Time-Series Analysis.
Pharmacoepidemiol Drug Saf
September 2024
Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.
Purpose: Since late 2017, the use of ulipristal acetate 5 mg (UPA; Proprietary name: Esmya) has been under review in the European Union, due to an emerging hepatic risk. In February 2018 and in July 2018, the Spanish Agency of Medicines and Medical Devices and the marketing authorization holder put two risk minimization measures (RMM) in place, in order to inform about new safety information and to mitigate this risk. This study aims to assess RMM effectiveness in Spain, by performing an interrupted time-series (ITS) analyses, between 2014 and 2019.
View Article and Find Full Text PDF[Is there still a place for progesterone receptor modulators in chronic use ?].
Rev Med Liege
September 2024
Service de Gynécologie-Obstétrique, CHU Liège, Belgique.
Selective progesterone receptor modulators (SPRMs) are synthetic steroid compounds that interact with the progesterone receptor, inducing various agonist, antagonist or mixed responses. First identified with mifepristone, they are now represented by ulipristal acetate (UPA), used for emergency contraception and uterine fibroids. Despite a few rare cases of severe hepatic insufficiency, SPRMs offer advantages in the treatment of uterine fibroids, reducing their volume without the hypoestrogenic side-effects of GnRH agonists, thus preserving patients' bone capital and quality of life.
View Article and Find Full Text PDFHormonal methods for emergency contraception.
Best Pract Res Clin Obstet Gynaecol
December 2024
Chalmers Sexual Health Centre, NHS Lothian, 2a Chalmers St, Edinburgh, EH3 9ES, United Kingdom; Centre for Reproductive Health, The University of Edinburgh, Edinburgh BioQuarter, Edinburgh, EH16 4UU, United Kingdom. Electronic address:
Article Synopsis
- The World Health Organization lists oral emergency contraception (EC) as an essential medicine, with ulipristal acetate (UPA) and levonorgestrel (LNG) being the recommended options.
- UPA is more effective than LNG, and both work by delaying ovulation, although they don't prevent implantation in the uterus.
- LNG is less effective for women with a higher body mass index or weight, and there are also other promising EC methods being researched, like LNG-releasing intrauterine devices.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!